Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Phase 3, Open-Label Study to Assess the Efficacy and Safety of 0.1 mmol/kg Omniscan (Gadodiamide Injection) for Magnetic Resonance Angiography (MRA) of the Aorto-iliac Arteries

NCT00209443 is registered in ClinicalTrials.gov with GE Healthcare as lead sponsor.

NCT NCT00209443
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00209443 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Phase 3, Open-Label Study to Assess the Efficacy and Safety of 0.1 mmol/kg Omniscan (Gadodiamide Injection) for Magnetic Resonance Angiography (MRA) of the Aorto-iliac Arteries
Lead sponsor
GE Healthcare
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2004
Completion date
February 28, 2006
Enrollment
407 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aorto-iliac stenosis, arterial occlusive diseases